Literature DB >> 1324959

Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure.

T Tsutamoto1, T Kanamori, A Wada, M Kinoshita.   

Abstract

OBJECTIVES: This study was designed to evaluate the role of endogenous atrial natriuretic peptide in the pulmonary circulation in patients with chronic heart failure.
BACKGROUND: Plasma atrial natriuretic peptide concentrations in patients with heart failure have been reported to be higher than those in normal subjects and to increase as the severity of heart failure progresses. Although endogenous atrial natriuretic peptide is thought to improve the condition of patients with heart failure by reducing preload and afterload, recent findings have indicated that a high plasma atrial natriuretic peptide level is a prognostic predictor in patients with heart failure.
METHODS: To evaluate the pathophysiologic role of endogenous atrial natriuretic peptide in the pulmonary circulation, plasma atrial natriuretic peptide and cyclic guanosine monophosphate (cGMP) levels were determined in the main pulmonary artery and pulmonary capillary wedge region in 80 patients with chronic congestive heart failure (New York Heart Association functional classes II to IV).
RESULTS: The plasma atrial natriuretic peptide level decreased significantly from the main pulmonary artery to the pulmonary capillary wedge region, whereas the plasma cGMP level increased significantly from the main pulmonary artery to the pulmonary capillary wedge region. In patients with mild chronic heart failure (n = 50), the plasma atrial natriuretic peptide level correlated with the cGMP level in the main pulmonary artery (gamma = 0.71, p less than 0.001). The atrial natriuretic peptide extraction level, calculated as (Atrial natriuretic peptide in the main pulmonary artery--Atrial natriuretic peptide in the pulmonary capillary wedge region) x Cardiac output x (1-hematocrit/100) (ng/min), also correlated with the cyclic guanosine monophosphate production level, calculated as (cGMP in the pulmonary capillary wedge region--cGMP in the main pulmonary artery) x Cardiac output x (1-hematocrit/100) (nmol/min) (gamma = 0.78, p less than 0.001). In contrast, such correlations were not found in patients with severe chronic heart failure (n = 30). In these patients, the atrial natriuretic peptide extraction level was significantly higher but there was no significant difference in the cGMP production level between the two groups (mild and severe chronic heart failure). Therefore, the molar ratio of cGMP production to atrial natriuretic peptide extraction in the pulmonary circulation was significantly lower in patients with severe chronic heart failure (88 +/- 16 vs. 480 +/- 41, p less than 0.001).
CONCLUSIONS: These results indicate that down-regulation of atrial natriuretic peptide receptors coupled to guanylate cyclase may occur in the pulmonary vascular beds of patients with severe chronic heart failure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324959     DOI: 10.1016/0735-1097(92)90005-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  Uncoupling of atrial natriuretic peptide and cyclic guanosine 3',5'-monophosphate production in patients with liver cirrhosis.

Authors:  K P Vorderwinkler; G Jakob; J Mair; G Judmaier; B Puschendorf
Journal:  Clin Investig       Date:  1994-01

2.  Plasma concentrations of adrenomedullin correlate with the extent of pulmonary hypertension in patients with mitral stenosis.

Authors:  T Nishikimi; S Nagata; T Sasaki; S Tomimoto; H Matsuoka; S Takishita; K Kitamura; A Miyata; H Matsuo; K Kangawa
Journal:  Heart       Date:  1997-10       Impact factor: 5.994

Review 3.  Endothelial actions of atrial and B-type natriuretic peptides.

Authors:  Michaela Kuhn
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A.

Authors:  Y Li; Y Saito; K Kuwahara; X Rong; I Kishimoto; M Harada; M Horiuchi; M Murray; K Nakao
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

5.  Approach to patients with heart failure and pulmonary hypertension.

Authors:  Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

6.  Ergometric exercise testing and sensitivity of cyclic guanosine 3',5'-monophosphate (cGMP) in diagnosing asymptomatic left ventricular dysfunction.

Authors:  G Jakob; J Mair; M Pichler; B Puschendorf
Journal:  Br Heart J       Date:  1995-02

7.  Alterations in the natriuretic hormone system related to cardiopulmonary bypass in infants with congestive heart failure.

Authors:  J M Costello; C L Backer; P A Checchia; C Mavroudis; R G Seipelt; D M Goodman
Journal:  Pediatr Cardiol       Date:  2004 Jul-Aug       Impact factor: 1.655

8.  Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat.

Authors:  L A Brown; D J Nunez; M R Wilkins
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

9.  Elevated pulmonary arterial and systemic plasma aldosterone levels associate with impaired cardiac reserve capacity during exercise in left ventricular systolic heart failure patients: A pilot study.

Authors:  Bradley A Maron; Thomas E Stephens; Laurie A Farrell; William M Oldham; Joseph Loscalzo; Jane A Leopold; Gregory D Lewis
Journal:  J Heart Lung Transplant       Date:  2015-10-19       Impact factor: 10.247

Review 10.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Authors:  Emily J Tsai; David A Kass
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.